Bluestar Genomics announced today that it received FDA breakthrough device designation for its pancreatic cancer test. San Diego-based Bluestar’s proprietary noninvasive pancreatic cancer detection test is designed for use with patients with new-onset diabetes, according to a news release. The test uses a standard blood draw to assess whether an individual has an abnormal epigenomic […]
Diagnostics
How CGM tech has advanced in the 21st century
The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control. Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history. Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in […]
PerkinElmer completes Oxford Immunotec acquisition
PerkinElmer (NYSE:PKI) announced today that it completed its previously announced acquisition of Oxford Immunotec. Under the acquisition agreement announced in January, London-based Oxford Immunotec’s shareholders will be entitled to receive $22 for each outstanding ordinary share, with the terms of the acquisition valuing Oxford Immunotec’s entire issued and to-be-issued ordinary share capital at $591 million. […]
Navidea enters into $5M private placement
Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it entered into a private placement worth $5 million. Dublin, Ohio-based Navidea’s agreement comes with its largest shareholder, John K. Scott, Jr., for the purchase of $5 million in newly-designated Series E redeemable convertible preferred stock, according to a news release. Over the course of the next 18 months, the […]
PerkinElmer to acquire Oxford Immunotec
PerkinElmer (NYSE:PKI) and Oxford Immunotec announced today that they agreed to terms under which the former will acquire the latter. Under the agreement, London-based Oxford Immunotec’s shareholders will be entitled to receive $22 for each outstanding ordinary share, with the terms of the acquisition valuing Oxford Immunotec’s entire issued and to-be-issued ordinary share capital at $591 […]
Biolinq names new CEO
Wearable biosensor technology developer Biolinq announced today that it named Richard Yang as its new CEO. San Diego-based Biolinq, which develops biosensor platforms to measure continuous glucose for managing diabetes, among other clinical conditions, said in a news release that Yang is a veteran of more than 20 years with time spent at top-tier medical device companies. […]
Abbott’s FreeStyle Libre 3 receives CE Mark
Abbott (NYSE:ABT) has won the CE Mark in the European Union for its next-generation FreeStyle Libre 3 continuous glucose monitoring system. Officials at Abbott boast that the Libre 3 technology includes a super small, thin sensor. It’s the size of two U.S. pennies stacked together and able to accurately provide real-time glucose readings over 14 days […]
PerkinElmer launches high-volume COVID-19 test workstations
PerkinElmer (NYSE:PKI) announced today that it launched a series of Explorer workstations for increasing COVID-19 testing capabilities. Waltham, Mass.-based PerkinElmer touts its Explorer workstations as capable of preparing and running up to 10,000 COVID-19 tests per day, enabling laboratories to ramp up their testing for the SARS-CoV-2 virus causing coronavirus and generate quick results. According to […]
BREAKING: Thermo Fisher drops bid for Qiagen
Thermo Fisher Scientific (NYSE:TMO) announced today that its offer to acquire Qiagen (NYSE:QGEN) in an $11.5 billion deal has lapsed. According to a news release, more than 107.5 million shares of Qiagen (47.02% of the issued and outstanding ordinary shares for the company) were validly tendered into the offer by the end of the acceptance period on Aug. […]
Report: Will Dr. Hahn crack under political pressure?
Many jobs have come with increased stress levels during the coronavirus pandemic, from ICU staff to Walmart greeters. Now officials who’ve been keeping tabs on FDA commissioner Dr. Stephen Hahn are wondering whether he can weather the strain of defending science while working for the Trump administration. Hahn has been squeezed between expressing his professional […]
